The NYSE Welcomes vVARDIS as a Publicly Listed Company

(NYSE: VVVV) vVARDIS has been welcomed as a publicly listed company on the New York Stock Exchange. The company was co-founded by Dr. Haley Abivardi and Dr. Goly Abivardi, who have spent 25 years developing a drill-free treatment for tooth decay. vVARDIS is a Swiss dental technology company focused on changing the way early tooth decay is treated. Its flagship product, Curodont® Repair Fluoride Plus, uses proprietary peptide technology to help repair early-stage tooth decay by supporting the natural remineralization of enamel, allowing treatment without drilling, needles, or fillings. Tooth decay is described as the world's #1 non-communicable disease, affecting 2.5 billion people globally. Nearly 90% of U.S. adults have experienced tooth decay, and nearly 73% report dental fear, with 21% avoiding the dentist due to anxiety. The Curodont® Repair Fluoride Plus technology has already treated more than 2.5 million teeth. The product is available in more than 20% of U.S. dental practices. vVARDIS aims to provide dentists with a way to treat early decay while making the experience easier and less intimidating for patients. The company highlights the significant unmet need for less invasive dental care solutions. The NYSE celebrated vVARDIS's IPO and its mission to reshape the future of dental care.